Many human diseases are inadequately treated because great molecular targets are intractable to even the best of today’s pharmaceutical approaches. At Nimbus, we aim to solve this dilemma.
Nimbus Discovery consists of an elite team of drug hunters passionate about creating medicines for sought-after disease targets. We have established a robust pipeline of novel agents that target a breadth of therapeutic areas, including immunological and inflammatory disorders, oncology and metabolic diseases. This pipeline is augmented by our strategy to apply human genomics to select patient populations enriched for responders to the mechanisms we target.
Nimbus’ unique physics-based approach for rational drug design enables us to overcome the limitations of traditional drug discovery practices and solve some of the most challenging problems in the industry. We focus on generating drugs against hard-to-drug targets that have a high probability of clinical success and would serve to treat substantial unmet medical needs.
In 2015, Nimbus will initiate clinical studies with its first-in-class allosteric ACC inhibitor, ND-630, in metabolic disease patients. Nimbus is also progressing pre-clinical stage programs that target IRAK4 and Tyk2, to address hematological tumors and autoimmune diseases, while continuing to discover new chemical matter against important, but challenging, targets where our insights are transformational.
Nimbus was named a Fierce 15 by FierceBiotech in 2013, designating it as one of the most promising private biotechnology companies in the industry.